Mylan Misses on Revenues but Beats on EPS
Mylan (NAS: MYL) reported earnings on Feb. 21. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Mylan missed slightly on revenues and beat expectations on earnings per share.
Compared with the prior-year quarter, revenue expanded and GAAP earnings per share grew.
Margins increased across the board.
Mylan recorded revenue of $1.53 billion. The 16 analysts polled by S&P Capital IQ anticipated sales of $1.56 billion on the same basis. GAAP reported sales were 6.7% higher than the prior-year quarter's $1.43 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.53. The 21 earnings estimates compiled by S&P Capital IQ anticipated $0.50 per share on the same basis. GAAP EPS of $0.30 for Q4 were much higher than the prior-year quarter's $0.00 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 42.1%, 170 basis points better than the prior-year quarter. Operating margin was 17.5%, 220 basis points better than the prior-year quarter. Net margin was 8.5%, 710 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.62 billion. On the bottom line, the average EPS estimate is $0.53.
Next year's average estimate for revenue is $6.87 billion. The average EPS estimate is $2.40.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 543 members out of 577 rating the stock outperform, and 34 members rating it underperform. Among 178 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 175 give Mylan a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mylan is outperform, with an average price target of $26.00.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Mylan the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.
- Add Mylan to My Watchlist.
At the time this article was published
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.